Baudax Bio, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Baudax Bio, Inc. is a pharmaceutical entity concentrating on therapeutic solutions for acute care environments. The company's primary commercial offering is ANJESO (meloxicam) injection, an intravenous non-opioid designed for managing moderate to severe pain, either as a standalone treatment or in conjunction with other non-NSAID analgesics. Beyond this, Baudax Bio maintains a development pipeline featuring novel neuromuscular blocking agents and their reversal compounds. This includes BX1000, an intermediate-acting agent that has demonstrated positive top-line final results from its Phase II clinical trial, and BX2000, an ultra-short acting agent in Phase I studies. Additionally, BX3000 is under preclinical investigation as a neuromuscular blockade reversal agent. The company also expanded its portfolio through the acquisition of TeraImmune, Inc., adding TI-168, a candidate for Hemophilia A patients with inhibitors, which has received Orphan Drug designation from the U.S. Food and Drug Administration. Established in 2019 and headquartered in Malvern, Pennsylvania, Baudax Bio filed for voluntary reorganization under Chapter 11 in February 2024, leading to the delisting of its common stock from Nasdaq.
Baudax Bio Announces Corporate Update
Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag
Why Is Baudax Bio (BXRX) Stock Up 75% Today?
Baudax Bio shares rocket as lead clinical candidate gains FDA orphan drug designation
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
Here's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock Now
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune
Why Is Baudax Bio (BXRX) Stock Up 130% Today?
Baudax Bio shares jump on acquisition of TeraImmune
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data
Baudax Bio Announces Date of Reconvened Annual Meeting
Baudax Bio to Present at the Sidoti Virtual Investor Conference
Why Is Baudax Bio (BXRX) Stock Down 52% Today?
Best Penny Stocks To Buy Now? 3 To Watch Today
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Why Is Baudax Bio (BXRX) Stock Up 50% Today?